Quote | Arcellx Inc. (NASDAQ:ACLX)
Last: | $53.29 |
---|---|
Change Percent: | -0.54% |
Open: | $52.46 |
Close: | $53.29 |
High: | $54.05 |
Low: | $51.32 |
Volume: | 295,359 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | Arcellx Inc. (NASDAQ:ACLX)
2024-05-02 10:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund rose 15.33%, outperforming the broade...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Message Board Posts | Arcellx Inc. (NASDAQ:ACLX)
Subject | By | Source | When |
---|---|---|---|
Going beast mode into next week. | bandit007 | investorshub | 06/10/2022 6:47:18 PM |
Nice correction coming here. New IPO at | TheyWantYourShares | investorshub | 04/01/2022 1:08:49 PM |
Net loss of $44M > no revenues! ( | crudeoil24 | investorshub | 02/04/2022 12:12:20 PM |
Arcellx Inc. ACLX, has set terms for its | crudeoil24 | investorshub | 02/02/2022 2:53:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Arcellx Inc. Company Name:
ACLX Stock Symbol:
NASDAQ Market:
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Health...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Th...
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...